Cardiac mTOR rescues the detrimental effects of diet-induced obesity in the heart after ischemia-reperfusion

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 12, 2015, Pages H1530-H1539

  Aoyagi, Toshinori ^a   Higa, Jason K ^a   Aoyagi, Hiroko ^a   Yorichika, Naaiko ^a   Shimada, Briana K ^a   Matsui, Takashi ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Diet induced obesity; Heart failure; Mammalian target of rapamycin; Metabolic syndrome; Myocardial infarction; Transgenic mice

Indexed keywords

BETA ACTIN; CREATINE KINASE; GROWTH DIFFERENTIATION FACTOR 15; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYOSIN HEAVY CHAIN ALPHA; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; MTOR PROTEIN, RAT; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET INDUCED OBESITY; EX VIVO STUDY; GLUCOSE INTOLERANCE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART RATE; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; SYSTOLIC BLOOD PRESSURE; WILD TYPE; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; ENZYMOLOGY; GENETICS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; LIPID DIET; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NECROSIS; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TIME; TRANSGENIC MOUSE; WEIGHT GAIN;

ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; GLUCOSE INTOLERANCE; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NECROSIS; OBESITY; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE; VENTRICULAR REMODELING; WEIGHT GAIN;

EID: 84931042268     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00008.2015     Document Type: Article

References (55)

1. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor CM, Diaz R, Belenkov YN, Var- shavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myo-cardial iNfarcTion (VALIANT) trial. Circulation 110: 1572–1578, 2004.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640–1645, 2009.
3. Ameri K, Harris AL. Activating transcription factor 4. Int J Biochem Cell Biol 40: 14–21, 2008.
4. Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamau-chi J, Tanoue A. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology 148: 2075–2084, 2007.
5. Aoyagi T, Kusakari Y, Xiao CY, Inouye BT, Takahashi M, Scherrer-Crosbie M, Rosenzweig A, Hara K, Matsui T. Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 303: H75–H85, 2012.
6. Aoyagi T, Matsui T. The cardiomyocyte as a source of cytokines in cardiac injury. J Cell Sci Ther 2011: S5–003, 2011.
7. Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N. Amino acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab 296: E592–E602, 2009.
8. Battiprolu PK, Hojayev B, Jiang N, Wang ZV, Luo X, Iglewski M, Shelton JM, Gerard RD, Rothermel BA, Gillette TG, Lavandero S, Hill JA. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest 122: 1109–1118, 2012.
9. Beaser RS, Levy P. Metabolic syndrome: a work in progress, but a useful construct. Circulation 115: 1812–1818, 2007.
10. Bucholz EM, Rathore SS, Reid KJ, Jones PG, Chan PS, Rich MW, Spertus JA, Krumholz HM. Body mass index and mortality in acute myocardial infarction patients. Am J Med 125: 796–803, 2012.
11. Buss SJ, Muenz S, Riffel JH, Malekar P, Hagenmueller M, Weiss CS, Bea F, Bekeredjian R, Schinke-Braun M, Izumo S, Katus HA, Hardt SE. Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J Am Coll Cardiol 54: 2435–2446, 2009.
12. Felkin LE, Narita T, Germack R, Shintani Y, Takahashi K, Sarath-chandra P, Lopez-Olaneta MM, Gomez-Salinero JM, Suzuki K, Barton PJ, Rosenthal N, Lara-Pezzi E. Calcineurin splicing variant cal-cineurin Afj1 improves cardiac function after myocardial infarction without inducing hypertrophy. Circulation 123: 2838-2847, 2011.
13. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 58: 88-111, 2008.
14. Gatica D, Chiong M, Lavandero S, Klionsky DJ. Molecular mechanisms of autophagy in the cardiovascular system. Circ Res 116: 456-467, 2015.
15. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 110: 1564-1571, 2004.
16. Gottlieb RA, Andres AM, Sin J, Taylor DP. Untangling autophagy measurements: all fluxed up. Circ Res 116: 504-514, 2015.
17. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: 433-438, 2004.
18. Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30: 35-42, 2005.
19. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. JAMA 294: 334-341, 2005.
20. Jousse C, Deval C, Maurin AC, Parry L, Cherasse Y, Chaveroux C, Lefloch R, Lenormand P, Bruhat A, Fafournoux P. TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway. J Biol Chem 282: 15851-15861, 2007.
21. Katz MY, Kusakari Y, Aoyagi H, Higa JK, Xiao CY, Abdelkarim AZ, Marh K, Aoyagi T, Rosenzweig A, Lozanoff S, Matsui T. Three-dimensional myocardial scarring along myofibers after coronary ischemia-reperfusion revealed by computerized images of histological assays. Physiol Rep 2: e12072, 2014.
22. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor- fj superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfu-sion injury. Circ Res 98: 351-360, 2006.
23. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kan-wischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17: 581-588, 2011.
24. Khan S, Salloum F, Das A, Xi L, Vetrovec GW, Kukreja RC. Rapamycin confers preconditioning-like protection against ischemia-rep-erfusion injury in isolated mouse heart and cardiomyocytes. J Mol Cell Cardiol 41: 256-264, 2006.
25. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 100: 1589-1596, 2007.
26. Koretsune Y, Marban E. Mechanism of ischemic contracture in ferret hearts: relative roles of [Ca2+]i elevation and ATP depletion. Am J Physiol Heart Circ Physiol 258: H9-H16, 1990.
27. Kusakari Y, Xiao CY, Himes N, Kinsella SD, Takahashi M, Rosenzweig A, Matsui T. Myocyte injury along myofibers in left ventricular remodeling after myocardial infarction. Interact Cardiovasc Thorac Surg 9: 951-955, 2009.
28. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 149: 274-293, 2012.
29. Maejima Y, Chen Y, Isobe M, Gustafsson AB, Kitsis RN, Sadoshima J. Recent progress in research on molecular mechanisms of autophagy in the heart. Am J Physiol Heart Circ Physiol 308: H259-H268, 2015.
30. McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S, Alderman JD, Ferguson JJ, Safian RD, Grossman W. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation 74: 693-702, 1986.
31. Miyazaki S, Fujiwara H, Onodera T, Kihara Y, Matsuda M, Wu DJ, Nakamura Y, Kumada T, Sasayama S, Kawai C, et al. Quantitative analysis of contraction band and coagulation necrosis after ischemia and reperfusion in the porcine heart. Circulation 75: 1074-1082, 1987.
32. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using trans-genic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 15: 1101–1111, 2004.
33. Mukamal KJ, Nesto RW, Cohen MC, Muller JE, Maclure M, Sherwood JB, Mittleman MA. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 24: 1422–1427, 2001.
34. Murcia AM, Hennekens CH, Lamas GA, Jimenez-Navarro M, Rouleau JL, Flaker GC, Goldman S, Skali H, Braunwald E, Pfeffer MA. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 164: 2273–2279, 2004.
35. Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, Ogawa W, del Monte F, Gwathmey JK, Grazette L, Hemmings B, Kass DA, Champion HC, Rosenzweig A. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest 115: 2128–2138, 2005.
36. Nakamura K, Aoyagi T, Hiroyama M, Kusakawa S, Mizutani R, Sanbe A, Yamauchi J, Kamohara M, Momose K, Tanoue A. Both V1A and V1B vasopressin receptors deficiency result in impaired glucose tolerance. Eur J Pharmacol 613: 182–188, 2009.
37. Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD, Hotamisligil GS. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell 29: 541–551, 2008.
38. Park SY, Cho YR, Kim HJ, Higashimori T, Danton C, Lee MK, Dey A, Rothermel B, Kim YB, Kalinowski A, Russell KS, Kim JK. Unraveling the temporal pattern of diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes 54: 3530–3540, 2005.
39. Reichelt ME, Willems L, Peart JN, Ashton KJ, Matherne GP, Blackburn MR, Headrick JP. Modulation of ischaemic contracture in mouse hearts: a ‘supraphysiological’ response to adenosine. Exp Physiol 92: 175–185, 2007.
40. Rodriguez-Sinovas A, Abdallah Y, Piper HM, Garcia-Dorado D. Reperfusion injury as a therapeutic challenge in patients with acute myocardial infarction. Heart Fail Rev 12: 207–216, 2007.
41. Sankaralingam S, Abo Alrob O, Zhang L, Jaswal JS, Wagg CS, Fukushima A, Padwal RS, Johnstone DE, Sharma AM, Lopaschuk GD. Lowering body weight in obese mice with diastolic heart failure improves cardiac insulin sensitivity and function: implications for the obesity paradox. Diabetes. 2014 Dec 18. p: db141050. [Epub ahead of print]. doi:10.2337/db14-1050.
42. Sciarretta S, Volpe M, Sadoshima J. Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res 114: 549–564, 2014.
43. Sciarretta S, Zhai P, Shao D, Maejima Y, Robbins J, Volpe M, Condorelli G, Sadoshima J. Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome. Circulation 125: 1134–1146, 2012.
44. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 15: 155-162, 2014.
45. Song X, Kusakari Y, Xiao CY, Kinsella SD, Rosenberg MA, Scherrer-Crosbie M, Hara K, Rosenzweig A, Matsui T. mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. Am J Physiol Cell Physiol 299: C1256-C1266, 2010.
46. Steenbergen C, Murphy E, Watts JA, London RE. Correlation between cytosolic free calcium, contracture, ATP, and irreversible ischemic injury in perfused rat heart. Circ Res 66: 135-146, 1990.
47. Thakker GD, Frangogiannis NG, Bujak M, Zymek P, Gaubatz JW, Reddy AK, Taffett G, Michael LH, Entman ML, Ballantyne CM. Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol 291: H2504-H2514, 2006.
48. Volkers M, Doroudgar S, Nguyen N, Konstandin MH, Quijada P, Din S, Ornelas L, Thuerauf DJ, Gude N, Friedrich K, Herzig S, Glem-botski CC, Sussman MA. PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity. EMBO Mol Med 6: 57-65, 2014.
49. Volkers M, Konstandin MH, Doroudgar S, Toko H, Quijada P, Din S, Joyo A, Ornelas L, Samse K, Thuerauf DJ, Gude N, Glembotski CC, Sussman MA. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage. Circulation 128: 2132-2144, 2013.
50. von Bibra H, St John Sutton M. Impact of diabetes on postinfarction heart failure and left ventricular remodeling. Curr Heart Fail Rep 8: 242-251, 2011.
51. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 72: 19-44, 2010.
52. Xu G, Watanabe T, Iso Y, Koba S, Sakai T, Nagashima M, Arita S, Hongo S, Ota H, Kobayashi Y, Miyazaki A, Hirano T. Preventive effects of heregulin-fj1 on macrophage foam cell formation and atherosclerosis. Circ Res 105: 500-510, 2009.
53. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830, 2003.
54. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98: 342-350, 2006.
55. Zhang Y, Xu X, Ren J. MTOR overactivation and interrupted autophagy flux in obese hearts: a dicey assembly? Autophagy 9: 939-941, 2013.